Evaluation of triple negative breast cancer with heterogeneous immune infiltration

被引:3
|
作者
Quintana, Angela [1 ]
Arenas, Enrique Javier [2 ,3 ]
Bernado, Cristina [2 ]
Navarro, Jose Fernandez [4 ]
Gonzalez, Jonatan [4 ]
Esteve-Codina, Anna [5 ,6 ]
Moline, Teresa [7 ]
Marti, Merce [8 ]
Curigliano, Giuseppe [9 ,10 ]
Schmid, Peter [11 ]
Peg, Vicente [3 ,7 ,12 ]
Arribas, Joaquin [2 ,3 ,13 ,14 ,15 ]
Cortes, Javier [1 ,16 ,17 ,18 ]
机构
[1] Vall dHebron Inst Oncol, Breast Canc Unit, Barcelona, Spain
[2] Vall dHebron Inst Oncol, Preclin Res Program, Barcelona, Spain
[3] Biomed Res Network Ctr Oncol CIBERONC, Madrid, Spain
[4] Vall dHebron Inst Oncol, Bioinformat Dept, Barcelona, Spain
[5] Barcelona Inst Sci & Technol BIST, Ctr Genom Regulat, CNAG CRG, Barcelona, Spain
[6] Univ Pompeu Fabra UPF, Barcelona, Spain
[7] Vall dHebron Univ Hosp, Dept Pathol, Barcelona, Spain
[8] Univ Autonoma Barcelona, Dept Biol Cellular Fisiol & Immunol, Barcelona, Spain
[9] European Inst Oncol, IRCCS, Milan, Italy
[10] Univ Milan, Dept Oncol & Hemato Oncol, Milan, Italy
[11] Queen Mary Univ London, Barts Canc Inst, London, England
[12] Univ Autonoma Barcelona, Dept Med, Barcelona, Spain
[13] Univ Pompeu Fabra, Dept Med & Ciencies Vida, Barcelona, Spain
[14] Catalan Inst Res & Adv Studies ICREA, Barcelona, Spain
[15] Inst Hosp Mar Invest Med IMIM, Canc Res Program, Barcelona, Spain
[16] Univ Europea Madrid, Fac Biomed & Hlth Sci, Dept Med, Madrid, Spain
[17] Int Breast Canc Ctr, Quironsalud Grp, Pangaea Oncol, Barcelona, Spain
[18] Med Scientia Innovat Res MedSIR, Barcelona, Spain
来源
FRONTIERS IN IMMUNOLOGY | 2023年 / 14卷
关键词
tumor-infiltrating lymphocytes; intratumor heterogeneity; triple negative breast cancer; transcriptomics; immune cell abundance; PEMBROLIZUMAB PLUS CHEMOTHERAPY; PROGNOSTIC VALUE; OPEN-LABEL; LYMPHOCYTES;
D O I
10.3389/fimmu.2023.1149747
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
IntroductionTumor infiltrating lymphocytes (TILs) are known to be a prognostic and predictive biomarker in breast cancer, particularly in triple negative breast cancer (TNBC) patients. International guidelines have been proposed to evaluate them in the clinical setting as a continuous variable, without a clear defined cut-off. However, there are scenarios where the immune infiltration is heterogeneous that some areas of the patient's tumour have high numbers of TILs while other areas completely lack them. This spontaneous presentation of a heterogeneous immune infiltration could be a great opportunity to study why some tumours present TILs at diagnosis but others do not, while eliminating inter patient's differences. MethodsIn this study, we have identified five TNBC patients that showed great TIL heterogeneity, with areas of low (<= 5%) and high (>= 50%) numbers of TILs in their surgical specimens. To evaluate immune infiltration heterogeneity, we performed and analyzed bulk RNA-sequencing in three independent triplicates from the high and low TIL areas of each patient. ResultsGene expression was homogeneous within the triplicates in each area but was remarkable different between TILs regions. These differences were not only due to the presence of TILs as there were other non-inflammatory genes and pathways differentially expressed between the two areas. DiscussionThis highlights the importance of intratumour heterogeneity driving the immune infiltration, and not patient's characteristics like the HLA phenotype, germline DNA or immune repertoire.
引用
收藏
页数:8
相关论文
共 50 条
  • [31] Immune Checkpoint Blockade in Patients with Triple-Negative Breast Cancer
    Michel, Laura L.
    von Au, Alexandra
    Mavratzas, Athanasios
    Smetanay, Katharina
    Schuetz, Florian
    Schneeweiss, Andreas
    TARGETED ONCOLOGY, 2020, 15 (04) : 415 - 428
  • [32] Immune-related biomarkers in triple-negative breast cancer
    Juan Zhang
    Qi Tian
    Mi Zhang
    Hui Wang
    Lei Wu
    Jin Yang
    Breast Cancer, 2021, 28 : 792 - 805
  • [33] IMMUNE RESPONSES DURING NEOADJUVANT CHEMOTHERAPY IN TRIPLE NEGATIVE BREAST CANCER
    Ghallab, Ahmed
    EXCLI JOURNAL, 2020, 19 : 1295 - 1296
  • [34] Immune profiling of paired primary and recurrent triple negative breast cancer
    He, Ting-Fang
    Yost, Susan
    Schmolze, Daniel
    Wang, Roger
    Rosario, Anthony
    Tu, Travis
    Chu, Peiguo
    Lee, Peter
    Yuan, Yuan
    CANCER RESEARCH, 2018, 78 (04)
  • [35] Immune Checkpoint Blockade in Patients with Triple-Negative Breast Cancer
    Laura L. Michel
    Alexandra von Au
    Athanasios Mavratzas
    Katharina Smetanay
    Florian Schütz
    Andreas Schneeweiss
    Targeted Oncology, 2020, 15 : 415 - 428
  • [36] Secreted breast tumor interstitial fluid microRNAs and their target genes are associated with triple-negative breast cancer, tumor grade, and immune infiltration
    Thilde Terkelsen
    Francesco Russo
    Pavel Gromov
    Vilde Drageset Haakensen
    Søren Brunak
    Irina Gromova
    Anders Krogh
    Elena Papaleo
    Breast Cancer Research, 22
  • [37] Secreted breast tumor interstitial fluid microRNAs and their target genes are associated with triple-negative breast cancer, tumor grade, and immune infiltration
    Terkelsen, Thilde
    Russo, Francesco
    Gromov, Pavel
    Haakensen, Vilde Drageset
    Brunak, Soren
    Gromova, Irina
    Krogh, Anders
    Papaleo, Elena
    BREAST CANCER RESEARCH, 2020, 22 (01)
  • [38] Triple Negative Breast Cancer
    Aneaus, Sheikh
    Kumar, Amit
    Induja, M. S.
    Tekam, Manish Kumar
    Mullasserri, Sileesh
    CURRENT SCIENCE, 2023, 125 (03): : 236 - 236
  • [39] Triple Negative Breast Cancer
    Cetin, Idil
    Topcul, Mehmet
    ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, 2014, 15 (06) : 2427 - 2431
  • [40] Triple negative breast cancer
    Collingridge, David
    LANCET ONCOLOGY, 2019, 20 (05): : 618 - 618